Everything is progressing well enough at NFL Biosciences in smoking cessation for the action to jump 50% in 3 sessions

Posted Jan 24, 2023, 12:23 PM

We can say that it was a press release that hit the mark… In the space of three sessions, NFL Biosciences shares jumped 45%, in view of the 3 euro threshold, which was worth only 54 cents on May 24 last year, at the lowest of its young stock market career, after an introduction on Alternext in June 2021 at nearly 4 euros.

The company is part of the world of biopharmaceuticals, whose business is to create drugs from existing molecules, mostly developed by biotechs. She specializes in helping with smoking cessation through research work on a botanical drug candidate, clinically developed, composed of natural proteins extracted from tobacco leaves and devoid of nicotine.

NFL, from 101 to 301

Called NFL-101, it is derived from a subcutaneous desensitization treatment which had been developed by the Pasteur Institute against allergies in tobacco factory workers, the company recalls in its press release. It is protected by two families of patents. Beyond NFL-101, NFL Biosciences is also leading projects to develop botanical drugs for the treatment of cannabis use disorder (NFL-201) and alcoholism (NFL-301).

In this press release published on January 20 before market, the management of the biopharma indicates that it is in phase with its plan of action within the framework of the phase II/III Cesto II study, intended to evaluate the efficacy and safety of NFL-101 in this smoking cessation indication. Everything is progressing according to schedule, assures NFL Biosciences.

232 recruitments to date

The study aims to include 318 smokers in order to demonstrate the effectiveness of NFL-101 against a placebo and to choose the most effective dose. Nine clinical centers are currently participating in the study: the University Hospitals of Bordeaux, Clermont-Ferrand, Dijon, Lorient, Marseille, Montpellier, Poitiers and Rennes, as well as the Eurofins-Optimed research institute in Grenoble.

To date, 232 subjects have already been recruited, with the company aiming to finalize recruitment during the second quarter, which would allow the results to be obtained on the main criteria by the end of 2023. The evaluation criterion The main criteria are continuous abstinence for four weeks, the secondary criteria being continuous abstinence for six months, number of cigarettes smoked, withdrawal symptoms and cravings.

Last October, the action had already benefited from the announcement of a partnership with the Indian group Themis Medicare to test the experimental treatment NFL-101 in the country, at no cost to the French company. . It is indeed Themis Medicare which took charge of ” the cost of the process, from submission to completion of the study “. The clinical trial must be carried out with 334 smokers and in the event of positive results, the Indian will buy from NFL Biosciences the commercial rights for the country. In addition to a fixed payment, the French company would also receive a double-digit percentage on sales (so more than 10%).

Also read:

NFL Biosciences’ experimental drug to cure tobacco addiction will also be tested in India



Leave a Comment

Your email address will not be published. Required fields are marked *